Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma

Am J Hematol. 2022 Jun 1;97(6):E195-E198. doi: 10.1002/ajh.26530. Epub 2022 Mar 21.

Authors

Meera Mohan¹, Sravani Gundarlapalli², Aniko Szabo¹, Naveen Yarlagadda³, Sunilkumar Kakadia³, Manojna Konda³, Anusha Jillella³, Amisha Fnu³, Yetunde Ogunsesan², Lakshmi Yarlagadda², Nishant Thalambedu², Hussain Munawar², Monica Graziutti², Samer Al Hadidi², Daisy Alapat⁴, Sharmilan Thanendrarajan², Maurizio Zangari², Frits van Rhee², Carolina Schinke²

Affiliations

¹ Medical College of Wisconsin, Froedtert Clinical Cancer Center, Division of Hematology/Oncology, Milwaukee, Wisconsin, USA.
² Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
³ Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
⁴ Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

PMID: 35285981
DOI: 10.1002/ajh.26530

No abstract available

Publication types

Letter

MeSH terms

Bone Marrow
Bone Marrow Transplantation
Hematopoietic Stem Cell Transplantation*
Humans
Multiple Myeloma* / therapy
Neoplasm, Residual
Receptors, Chimeric Antigen*
Stem Cell Transplantation
Transplantation, Autologous

Substances

Receptors, Chimeric Antigen

Associated data

ClinicalTrials.gov/NCT04140162
ClinicalTrials.gov/NCT04436029
ClinicalTrials.gov/NCT04876248
ClinicalTrials.gov/NCT05091372
ClinicalTrials.gov/NCT04934475